Prevalence of molecular markers of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from West Africa during 2012–2022 Authors: Ruimin Zhou, Suhua Li, Penghui Ji, Shucheng Ruan, Ying Liu, Chengyun Yang, Dan Qian, Zhiquan He, Dan Wang, Deling Lu, Hongwei Zhang, Yan Deng Published: 2024 ABSTRACT AbstractSulfadoxine-pyrimethamine (SP) is a key drug recommended by the World Health Organization for the chemoprevention of malaria. However, the strategy is affected by the parasite resistance to SP. This study evaluated Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and dihydropteroate synthase (Pfdhps) genes, associated with SP resistance, from 508 P. falciparum isolates imported from West African countries to Henan Province, China, during 2012–2022. High mutant prevalence of the genes Pfdhfr (94.7%) and Pfdhps (96.8%) was observed. The mutants Pfdhfr N51I, C59R, S108N, and Pfdhps A437G were at high frequency in all countries analyzed. The overall prevalence of the mutant Pfdhps K540E was low (3.4%), but with a high frequency in Liberia (24.3%). The frequency of mutants Pfdhps I431V, A581G, and A613S was 11.7%, 9.8%, and 16.2%, respectively, all of which had the highest mutant prevalence in Nigeria. The mutant Pfdhps A581G and A613S were identified in the absence of K540E. The partially resistant haplotype (I51R59N108 - G437) was the most common (72.6%), and the fully resistant haplotype (I51R59N108 - G437E540) had a low prevalence of 3.4% and mainly occurred in Liberia. No super resistant haplotype was identified. The mutant Pfdhps I431V and the octuple mutant haplotype I51R59N108 - V431A436G437G581S613 deserve more attention. In areas of high SP resistance, the intervention still reduces low birthweight and maternal anaemia. SP should continue to be used in areas of high SP resistance until more effective alternatives for malaria chemoprevention are found. It is important to continuously monitor the molecular markers associated with SP resistance to better implement intermittent preventive treatment policies in pregnancy (IPTp) and infants (IPTi).Subject terms: Molecular biology, Diseases, Medical research Introduction Malaria is a serious global public health problem, particularly affecting the health of children and pregnant women. Worldwide, there were about 247 million malaria cases in 2021, with estimated 234 million cases in the World Health Organization (WHO) African region, accounting for about 95% of the total1. An estimated 13.4 million additional malaria cases were recorded between 2019 and 2021 with disruption to services during the COVID-19 pandemic, and the majority of these also were from countries in the WHO African region1. There were 15 malaria-endemic countries in West Africa in 2021, with 120 million estimated malaria cases reported, accounting for 51.3% of the estimated total in the entire WHO African region1. Meanwhile, approximately 328,000 deaths occurred in West Africa in 2021, and most deaths (80%) were in children under 5 years of age1. In the WHO African Region, about 13.3 million pregnant women were exposed to malaria infection in 2021, with the highest prevalence (40.7%) in West Africa1. The pregnant women and children under 5 years old are vulnerable populations, who are at highest risk of severe malaria. Preventive chemotherapy is an important strategy for malaria control worldwide, especially in areas with moderate to high malaria transmission. Sulfadoxine-pyrimethamine (SP) is recommended by the WHO as a key preventive chemotherapy drug. Due to the spread of chloroquine resistance in the 1960s2, SP combination therapy was adopted as a first-line drug to treat uncomplicated Plasmodium falciparum. It too was soon withdrawn as a treatment for clinical malaria because of resistance emergence3. However, it continued to be recommended for intermittent preventive treatment of malaria in pregnancy (IPTp) and infants (IPTi)4–6. The drug has been shown to be safe, effective, and cost-effective in reducing disease burden and saving lives. Recently updated and published WHO guidance7 includes three key strategies: seasonal malaria chemoprevention (SMC), perennial malaria chemoprevention (PMC) as a replacement for IPTi, and intermittent preventive treatment of malaria in pregnancy (IPTp). The strong recommendation by WHO has reaffirmed the use of IPTp-SP in areas with moderate to high malaria transmission. Compared with the original recommendations, the updated guidelines are less restrictive regarding age, dose, transmission intensity, and specific drugs. Nevertheless, the preventive effectiveness of SP is affected by the parasite resistance to the drugs. P. falciparum resistance to SP is affected by single nucleotide polymorphisms at specific codons in the two genes P. falciparum dihydropteroate synthase (Pfdhps) and dihydrofolate reductase (Pfdhfr), both of which are involved in the folate biosynthesis pathway. The polymorphisms of the Pfdhps and Pfdhfr genes are associated with resistance to sulfadoxine and pyrimethamine, respectively8,9. Most studies have indicated that SP resistance is related to mutations at codons S436A/F, A437G, K540E, A581G, and A613S/T in Pfdhps genes and N51I, C59R, S108N, and I164L in Pfdhfr genes10–13. A novel mutation I431V in Pfdhps genes was first detected in Nigeria in 2007, then in some other countries of West and Central Africa14–17. In most cases, the mutation I431V occurs simultaneously with four other Pfdhps mutations: S436A, A437G, A581G, and A613S, forming a quintuple mutant V431A436G437K540G581S61318. The combination of mutations in Pfdhfr and Pfdhps genes is strongly correlated with the clinical failure of SP treatment19–21. In addition, the type and number of mutant codons affect the level of SP resistance. Resistance levels are classified as follows: partially resistant consists of mutations of Pfdhfr I51R59N108 and Pfdhps G437 (I51R59N108-G437); fully resistant additionally includes Pfdhfr I51R59N108 and Pfdhps G437E540 (I51R59N108-G437E540); and the super resistant classification includes fully resistant mutations and the additional mutants Pfdhfr I164L and/or Pfdhps A581G and/or A613S/T22. It is essential to monitor the effectiveness of drugs for the better implementation of preventive chemotherapy strategies in malaria control. Surveillance of the molecular markers associated with drug resistance is one way to assess its spread. The Pfdhps and Pfdhfr genes associated with SP resistance are used to evaluate the effectiveness of SP in the SMC, PMC, and IPTp chemoprevention strategies. This study aimed to assess the distribution and prevalence of Pfdhps and Pfdhfr genes in imported cases of P. falciparum from West African countries to Henan Province during 2012–2022 and to add to the knowledge on molecular markers related to SP resistance. Results General characteristics A total of 508 P. falciparum infections imported from West Africa were reported in Henan Province, China, during 2012 − 2022. All 508 cases were imported from 11 countries in West Africa, with six countries accounting for more than 90% of the cases: Nigeria (35.0%, 178/508), Guinea (16.3%, 83/508), Ghana (12.4%, 63/508), Sierra Leone (10.0%, 51/508), Côte d’Ivoire (9.3%, 47/508), and Liberia (8.7%, 44/508) (Table 1). The temporal distribution of cases was relatively stable from 2012 to 2019; however, the number of cases decreased sharply due to the COVID-19 pandemic in 2020 − 2022 (Table 1). All but one Nigerian and one Liberian were Chinese citizens who traveled to countries in West Africa and returned with malaria infection. The ratio of female to male was 1:38.1, with a total of 13 females. The average age was 38.36 ± 10.16 years (range, 19 − 70 years). Among all cases, migrant workers accounted for 77.4% (393/508). Table 1Plasmodium falciparum infected cases imported from west African countries to Henan Province, China, during 2012–2022.Countries20122013201420152016201720182019202020212022Total (%)Nigeria2314281318271531414178 (35.0)Guinea8941747121910283 (16.3)Ghana58681386710163 (12.4)Sierra Leone10786743401151 (10.0)Côte d’Ivoire10353971630047 (9.3)Liberia51085285100044 (8.7)Benin02501101000019 (3.7)Togo0060002110010 (2.0)Mali113000020007 (1.4)Senegal000020110015 (1.0)Burkina Faso000100000001 (0.2)Total (%)53 (10.4)51 (10.0)71 (14.0)55 (10.8)50 (9.8)64 (12.6)51 (10.0)92 (18.1)10 (2.0)2 (0.4)9 (1.8)508 (100.0) Plasmodium falciparum infected cases imported from west African countries to Henan Province, China, during 2012–2022. Pfdhfr alleles The Pfdhfr gene was successfully sequenced from 473 P. falciparum isolates. Six mutant alleles of the Pfdhfr gene were identified: N51I, C59R, D87H, S108N, S120R, and I164L. The mutant alleles D87H, S120R, and I164L were detected in only one isolate each. The mutant D87H allele was isolated from the sample from Guinea, and the mutant S120R and I164L alleles were identified from Nigeria. By contrast, the prevalence of the mutant N51I, C59R, and S108N alleles was high and appeared in all 11 countries sampled, accounting for 91.3% (432/473), 91.8% (434/473), and 94.7% (448/473), respectively (Table 2). Compared with other countries, the prevalence of the mutant S108N alleles was lower in Senegal, Côte d’Ivoire, Togo, and Guinea (x2 = 17.434, p < 0.05). There was no significant difference in the prevalence of the mutant N51I, C59R, and S108N alleles from 2012 to 2022 (Fig. 1A). Table 2Prevalence of pfdhfr alleles and haplotypes detected in Plasmodium falciparum isolates from west African countries.Country (No. of isolates)Alleles*Haplotypes#N51IC59RS108NNCSINCNIICNINRNIIRNITotal (n = 473)432 (91.3)434 (91.8)448 (94.7)25 (5.3)3 (0.6)11 (2.3)13 (2.7)420 (88.8)Nigeria (n = 171)159 (93.0)158 (92.4)166 (97.1)5 (2.9)2 (1.2)6 (3.5)5 (2.9)152 (88.9)Guinea (n = 79)70 (88.6)69 (87.3)71 (89.9)8 (10.1)1 (1.3)1 (1.3)069 (87.3)Ghana (n = 59)53 (89.8)56 (94.9)57 (96.6)2 (3.4)01 (1.7)4 (6.8)52 (88.1)Côte d’Ivoire (n = 45)36 (80.0)39 (86.7)39 (86.7)6 (13.3)003 (6.7)36 (80.0)Sierra Leone (n = 44)41 (93.2)41 (93.2)42 (95.5)2 (4.5)01 (2.3)1 (2.3)40 (90.9)Liberia (n = 37)37 (100)36 (97.3)37 (100)001 (2.7)036 (97.3)Benin (n = 17)17 (100)17 (100)17 (100)000017 (100)Togo (n = 9)8 (88.9)8 (88.9)8 (88.9)1 (11.1)0008 (88.9)Mali (n = 6)6 (100)5 (83.3)6 (100)0.001 (16.7)05 (83.3)Senegal (n = 5)4 (80.0)4 (80.0)4 (80.0)1 (20.0)0004 (80.0)Burkina Faso (n = 1)1 (100)1 (100)1 (100)00001 (100) x 2 15.54310.65717.43417.43410.6789.03511.00910.606P value0.0790.3240.0390.0391.0000.5670.3260.336*The mutant D87H allele was isolated from the sample of Guinea; the mutant S120R and I164L alleles were all identified from Nigeria.#One haplotype IRNL was detected in the isolate from Nigeria in 2012.Boldface type indicates the mutant amino acid. Prevalence of pfdhfr alleles and haplotypes detected in Plasmodium falciparum isolates from west African countries. *The mutant D87H allele was isolated from the sample of Guinea; the mutant S120R and I164L alleles were all identified from Nigeria. #One haplotype IRNL was detected in the isolate from Nigeria in 2012. Boldface type indicates the mutant amino acid. Prevalence of alleles and haplotypes in Pfdhfr (A) and Pfdhps (B) genes detected in Plasmodium falciparum isolates from West African countries during 2012–2022. Pfdhfr haplotypes The mutant D87H and S120R alleles of the Pfdhfr gene were excluded from the haplotype construction. Using the codons N51I, C59R, S108N, and I164L in the Pfdhfr gene, six haplotypes were observed among the 473 isolates. The wild-type haplotype N51C59S108I164 was carried by 5.3% (25/473) of the isolates. The prevalence of wild-type haplotype NCSI from Senegal, Côte d’Ivoire, and Guinea was lower than from other countries (x2 = 17.434, p < 0.05). The most common mutant haplotype of the Pfdhps gene was the triple mutant IRNI (88.8%, 420/473), followed by the double mutants NRNI (2.7%, 13/473) and ICNI (2.3%, 11/473). The single mutant NCNI was identified in three isolates, and the quadruple mutant IRNL was detected in only one isolate from Nigeria (Table 2). There was no significant difference in the prevalence of the haplotypes NCSI, NCNI, ICNI, NRNI, and IRNI from 2012 to 2022 (Fig. 1A). Pfdhps alleles For the Pfdhps gene, 469 isolates were successfully sequenced. Nine mutant alleles were identified: I431V, S436A, S436F, A437G, I484T, K540E, A581G, A613S, and H614L. The mutant A437G allele was the most common and identified in all 11 countries, accounting for 84.4% (396/469). However, the prevalence of mutant A437G in Senegal (40.0%, 2/5), Mali (66.7%, 4/6), Guinea (72.4%, 56/77), and Sierra Leone (74.4%, 32/43) was lower than in other countries (x2 = 29.067, p < 0.01). There were two types of mutations at codon 436: S436A (47.8%, 224/469) and S436F (1.1%, 5/469). Almost half of the Pfdhps isolates (48.8%, 229/469) harbored the mutant S436A/F alleles. The mutant S436F allele was identified in four isolates from Nigeria and one from Benin and was always coexistent with the A613S allele. The mutant A613S, I431V, A581G, and K540E alleles were detected in 16.2% (76/469), 11.7% (55/469), 9.8% (46/469), and 3.4% (16/469) of the isolates, respectively (Table 3). The mutant I484T and H614L alleles were rarely reported, each of them was detected in two isolates in this study. Prevalences of the mutant I431V (27.5%, 47/171), A581G (22.2%, 38/171), and A613S (29.2%, 50/171) alleles in Nigeria were all significantly higher than in other countries (I431V, x2 = 73.540, p < 0.01; A581G, x2 = 55.398, p < 0.01; A613S, x2 = 43.284, p < 0.01). Meanwhile, the proportion of the K540E allele in Liberia (24.3%, 9/37) was significantly higher than that in other countries (x2 = 39.064, p < 0.01). As shown in Fig. 1B, the frequency of the I431V, S436A/F, A437G, K540E, A581G, and A613S alleles all showed a trend of increasing from 2012 to 2022, but the difference was not statistically significant. Table 3Prevalence of Pfdhps alleles and haplotypes detected in Plasmodium falciparum isolates from west African countries.Alleles/haplotypesTotal (n = 469)Nigeria (n = 171)Guinea (n = 77)Ghana (n = 58)Côte d’Ivoire (n = 45)Sierra Leone (n = 43)Liberia (n = 37)Benin (n = 17)Togo (n = 9)Mali (n = 6)Senegal (n = 5)Burkina Faso (n = 1)x2P valueAlleles I431V55 (11.7)47 (27.5)01 (1.7)2 (4.4)1 (2.3)3 (8.1)1 (5.9)000073.5400.000 S436A/F229 (48.8)88 (51.5)31 (40.3)35 (60.3)24 (53.3)20 (46.5)13 (35.1)7 (41.2)4 (44.4)5 (83.3)2 (40.0)014.2020.164 A437G396 (84.4)148 (86.5)56 (72.7)55 (94.8)40 (88.9)32 (74.4)33 (89.2)16 (94.1)9 (100)4 (66.7)2 (40.0)1 (100)29.0670.001 K540E16 (3.4)01 (1.3)2 (3.4)1 (2.2)3 (7.0)9 (24.3)0000039.0640.000 A581G46 (9.8)38 (22.2)01 (1.7)2 (4.4)1 (2.3)3 (8.1)1 (5.9)000055.3980.000 A613S76 (16.2)50 (29.2)5 (6.5)2 (3.4)7 (15.6)3 (7.0)5 (13.5)3 (17.6)01 (16.7)0043.2840.000Wild-type I431S436A437K540A581A61315 (3.2)6 (3.5)4 (5.2)01 (2.2)2 (4.7)1 (2.7)0001 (20.0)09.3900.525Single mutant ISGKAA204 (43.5)72 (42.1)41 (53.2)21 (36.2)19 (42.2)18 (41.9)14 (37.8)10 (58.8)5 (55.6)1 (16.7)2 (40.0)1 (100)10.7130.380 IAAKAA50 (10.7)11 (6.4)17 (22.1)3 (5.2)4 (8.9)9 (20.9)2 (5.2)002 (33.3)2 (40.0)030.7330.001Double mutant IAGKAA86 (18.3)15 (8.8)9 (11.7)28 (48.3)13 (28.9)7 (16.3)4 (10.8)4 (23.5)4 (44.4)2 (33.3)0053.1790.000 ISGEAA16 (3.4)01 (1.3)2 (3.4)1 (2.2)3 (7.0)9 (24.3)0000039.0640.000 IFAKAS5 (1.1)4 (2.3)000001 (5.9)00009.8030.458 ISGKGA3 (0.6)3 (1.8)00000000006.0870.808 VAAKAA2 (0.4)2 (1.2)00000000004.0510.945Triple mutant IAGKAS33 (7.0)13 (7.6)5 (6.5)2 (3.4)5 (11.1)3 (7.0)3 (8.1)1 (5.9)01 (16.7)005.4080.862 VAGKAA10 (2.1)8 (4.7)01 (1.7)001 (2.7)0000012.8320.233 VAAKGA1 (0.2)000001 (2.7)000005.1050.884 VSGKGA1 (0.2)1 (0.6)00000000002.0220.996 IAGKGA1 (0.2)001 (1.7)000000004.1960.938Quadruple mutant VAGKGA3 (0.6)3 (1.8)00000000006.0870.808 VAGKAS2 (0.4)2 (1.2)00000000004.0510.945 VSGKGS1 (0.2)1 (0.6)00000000002.0220.996 IAGKGS1 (0.2)000001 (2.7)000005.1050.884Quintuple mutant VAGKGS35 (7.5)30 (17.5)002 (4.4)1 (2.3)1 (2.7)1 (5.9)000047.4980.000Boldface type indicates the mutant amino acid. Prevalence of Pfdhps alleles and haplotypes detected in Plasmodium falciparum isolates from west African countries. Boldface type indicates the mutant amino acid. Pfdhps haplotypes The mutant I484T and H614L alleles were excluded to construct the haplotypes of the Pfdhfr gene. This study identified 18 Pfdhps haplotypes, including wild-type, single, double, triple, quadruple, and quintuple mutations. Only 15 isolates were without any point mutant, accounting for 3.2% (15/469). Single-mutant haplotypes were common, including ISGKAA (43.5%, 204/469) and IAAKAA (10.7%, 50/469). The IAAKAA haplotype proportions in Senegal (40.0%, 2/5), Guinea (22.1%, 17/77), and Sierra Leone (20.9%, 9/43) were significantly higher than in other countries (x2 = 30.733, p < 0.01). Five double mutant haplotypes were detected, including IAGKAA (18.3%, 86/469), ISGEAA (3.4%, 16/469), IFAKAS (1.1%, 5/469), ISGKGA (0.6%, 3/469), and VAAKAA (0.4%, 2/469). The prevalence of the IAGKAA haplotype in Ghana (48.3%, 28/58), Togo (44.4%, 4/9), and Mali (33.3%, 2/6) was significantly higher than in other countries (x2 = 53.179, p < 0.01). The highest prevalence of the ISGEAA haplotype was identified in Liberia, at 24.3% (9/37) among the countries in the study (x2 = 39.064, p < 0.01). Of the five triple mutant haplotypes detected, the VAAKGA, VSGKGA, and IAGKGA haplotypes were identified in one isolate. The other two were IAGKAS (7.0%, 33/469) and VAGKAA (2.1%, 10/469). Similarly, four quadruple haplotypes were detected with low prevalence: VAGKGA (0.6%, 3/469), VAGKAS (0.4%, 2/469), VSGKGS (0.2%, 1/469), and IAGKGS (0.2%, 1/469). The quintuple mutant haplotype VAGKGS was found in isolates from five countries: Nigeria (17.5%, 30/469), Côte d’Ivoire (4.4%, 2/45), Sierra Leone (2.3%, 1/43), Liberia (2.7%, 1/37), and Benin (5.9%, 1/17), with Nigeria having the highest prevalence (x2 = 47.498, p < 0.01) (Table 3). The prevalence of IAAKAA haplotype decreased from 2012 to 2022 (x2 = 10.865, p < 0.05), while there was no significant change in that of the other haplotypes (Fig. 1B). Combination of the Pfdhfr and Pfdhps Haplotypes Among all 508 P. falciparum cases, 468 isolates were successfully sequenced for the Pfdhfr and Pfdhps genes. A total of 37 haplotypes were obtained by combining the Pfdhfr and Pfdhps haplotypes. Five isolates were wild type, accounting for 1.1% (5/468). The IRNI-ISGKAA haplotype (39.1%, 183/468) was most prevalent in West Africa, followed by IRNI-IAGKAA (16.0%, 75/468), IRNI-IAAKAA (9.6%, 45/468), IRNI-VAGKGS (7.3%, 34/468), and IRNI-IAGKAS (6.0%, 28/468). Table 4 shows detailed information. The partially resistant haplotype with the I51R59N108 - G437 mutant was identified in 72.6% (340/468) of the isolates, including 13 haplotypes of the combined Pfdhfr and Pfdhps gene. There was no significant difference in the prevalence of the partially resistant haplotype among the countries (x2 = 17.332, p > 0.05). The fully resistant haplotype with the I51R59N108 - G437E540 mutant accounted for 3.4% (16/468) and was identified in five countries: Guinea (1.3%, 1/77), Ghana (3.4%, 2/58), Côte d’Ivoire (2.3%, 1/44), Sierra Leone (7.0%, 3/43), and Liberia (24.3%, 9/37). Liberia had the highest prevalence of the fully resistant haplotype compared with other countries (x2 = 37.875, p < 0.01). No super resistant haplotype was found in our study. Table 4Prevalence of Pfdhfr-Pfdhps haplotypes detected in Plasmodium falciparum isolates from west African countries.Pfdhfr and Pfdhps haplotypesNo. of mutant codonsNigeria (n = 171)Guinea (n = 77)Ghana (n = 58)Côte d’Ivoire (n = 44)Sierra Leone (n = 43)Liberia (n = 37)Benin (n = 17)Togo (n = 9)Mali (n = 6)Senegal (n = 5)Burkina Faso (n = 1)Total (n = 468)Undefinitive resistant NCSI-ISAKAA01 (0.6)2 (2.6)01 (2.3)1 (2.3)0000005 (1.1) NCSI-ISGKAA12 (1.2)3 (3.9)2 (3.4)1 (2.3)0001 (11.1)0009 (1.9) NCSI-IAAKAA101 (1.3)001 (2.3)00001 (20.0)03 (0.6) NCNI-ISAKAA101 (1.3)0000000001 (0.2) NCSI-IAGKAA201 (1.3)02 (4.5)00000003 (0.6) NCNI-ISGKAA21 (0.6)00000000001 (0.2) ICNI-ISAKAA2000001 (2.7)000001 (0.2) NCSI-IAGKAS31 (0.6)002 (4.5)00000003 (0.6) NCSI-VAGKAA31 (0.6)00000000001 (0.2) ICNI-ISGKAA32 (1.2)1 (1.3)0000000003 (0.6) ICNI-IAAKAA300001 (2.3)0001 (16.7)002 (0.4) IRNI-ISAKAA35 (2.9)1 (1.3)001 (2.3)00001 (20.0)08 (1.7) NRNI-ISGKAA32 (1.2)03 (5.2)2 (4.5)00000007 (1.5) NCNI-IAGKAS41 (0.6)00000000001 (0.2) IRNI-IAAKAA411 (6.4)16 (20.8)3 (5.2)4 (9.1)7 (16.3)2 (5.4)001 (16.7)1 (20.0)045 (9.6) ICNI-IAGKAA43 (1.8)01 (1.7)000000002 (0.4) ICNI-ISGKGA41 (0.6)00000000001 (0.2) NRNI-IAGKAA41 (0.6)01 (1.7)1 (2.3)1 (2.3)0000002 (0.4) NRNI-VAGKAA51 (0.6)00000000001 (0.2) NRNI-IAGKAS51 (0.6)00000000001 (0.2) IRNI-IFAKAS54 (2.3)000001 (5.9)00005 (1.1) IRNI-VAAKAA52 (1.2)00000000002 (0.4) IRNI-VAAKGA6000001 (2.7)000001 (0.2)Subtotal40 (23.4)26 (33.8)10 (17.2)13 (29.5)12 (27.9)4 (10.8)1 (5.9)1 (11.1)2 (33.3)3 (60.0)0112 (23.9)Partially resistant IRNI-ISGKAA464 (37.4)37 (48.1)16 (27.6)16 (36.4)18 (41.9)14 (37.8)10 (58.8)4 (44.4)1 (16.7)2 (40.0)1 (100)183 (39.1) IRNI-IAGKAA511 (6.4)8 (10.4)26 (44.8)10 (22.7)6 (14.0)4 (10.8)4 (23.5)4 (44.4)2 (33.3)0075 (16.0) IRNI-ISGKGA52 (1.2)00000000002 (0.4) IRNL-ISGKAA51 (0.6)00000000001 (0.2) IRNI-VSGKGA61 (0.6)00000000001 (0.2) IRNI-IAGKAS610 (5.8)5 (6.5)2 (3.4)3 (6.8)3 (7.0)3 (8.1)1 (5.9)01 (16.7)0028 (6.0) IRNI-VAGKAA66 (3.5)01 (1.7)001 (2.7)000008 (1.7) IRNI-IAGKGA6001 (1.7)000000001 (0.2) IRNI-VAGKGA73 (1.8)00000000003 (0.6) IRNI-VAGKAS72 (1.2)00000000002 (0.4) IRNI-VSGKGS71 (0.6)00000000001 (0.2) IRNI-IAGKGS7000001 (2.7)000001 (0.2) IRNI-VAGKGS830 (17.5)001 (2.3)1 (2.3)1 (2.7)1 (5.9)000034 (7.3)Subtotal131 (76.6)50 (64.9)46 (79.3)30 (68.2)28 (65.1)24 (64.9)16 (94.1)8 (88.9)4 (66.7)2 (40.0)1 (100)340 (72.6)Fully resistant IRNI-ISGEAA501 (1.3)2 (3.4)1 (2.3)3 (7.0)9 (24.3)0000016 (3.4)Boldface type indicates the mutant amino acid. Prevalence of Pfdhfr-Pfdhps haplotypes detected in Plasmodium falciparum isolates from west African countries. Boldface type indicates the mutant amino acid. Discussion Malaria in West Africa accounted for almost half of all cases globally in 2021, with Nigeria having the highest prevalence worldwide1. In this study, 508 P. falciparum-infected cases were imported from 11 out of the 15 malaria-endemic countries in West Africa, with Nigeria (35.0%) and Guinea (16.3%) accounting for half of the total cases. The recommended strategy of using SP to treat pregnant women with malaria, known as IPTp-SP, has played an important role in reducing neonatal mortality, low birthweight, and maternal anemia22,23. However, the effectiveness of IPTp-SP is threatened by the high prevalence and spread of SP resistance, especially in Africa24. Mutations in the Pfdhfr gene have been attributed to the inhibition constant (Ki) for pyrimethamine, and the Pfdhfr mutations N51I, C59R, S108N, and I164L are considered critical for the generation of pyrimethamine resistance25. The Pfdhfr mutant alleles N51I, C59R, and S108N have been found to be highly prevalent and widespread in Africa, as well as the triple mutant Pfdhfr I51R59N108 haplotype. Almost all had a prevalence of over 90%17,23–26. Previous research also showed the mutant Pfdhfr I164L had a high frequency in Asia, with relatively low prevalence in Africa27–29. Similarly, our study revealed that the Pfdhfr mutants N51I, C59R, and S108N had more than 90% prevalence in West African countries, except for Senegal, Côte d’Ivoire, Togo, and Guinea, which had less. The triple mutant IRNI (88.8%) was the most common haplotype of Pfdhfr. Meanwhile, the mutation I164L was detected in only one isolate from Nigeria in 2012. The prevalence of the mutants N51I, C59R, and S108N did not change significantly during the years 2012–2022. This was probably because those mutants had reached a very high frequency, and the mutations were fixed in the parasite population. It has been inferred that S108N, as a critical intermediate mutant, occurred first. Then, as it was followed by either N51I, C59R, and/or I164L mutations, the level of pyrimethamine resistance increased further25. As shown in Table 2, the Pfdhfr S108N mutant in our study had higher or equivalent frequency compared with N51I and C59R in all countries. For the Pfdhps gene, the mutant alleles A437G and K540E are key to SP resistance. Studies have shown that the triple mutant haplotype I51R59N108, in combination with the mutant Pfdhps A437G and K540E to form the quintuple mutant haplotype I51R59N108 - G437E540, is strongly associated with an increased risk of SP treatment failure30,31. The prevalence of the triple mutant haplotype I51R59N108 and the mutant Pfdhps A437G is very high in Africa, so the frequency of the mutant Pfdhps K540E could be used as a surrogate marker for the quintuple haplotype I51R59N108 - G437E540. The sextuple haplotype I51R59N108 - G437E540G518 is formed with the additional mutation of Pfdhps A581G and has been associated with the increase of the IPTp-SP, resulting in low infant birth weight and increasing placental inflammation32–34. In 2010, the IPTi-SP was not recommended for areas where the prevalence of the mutant Pfdhps K540E exceeded 50%; however, the presence of the mutant Pfdhps A581G did not yet influence IPTi policy35. In 2013, the WHO Evidence Review Group recommended that IPTp-SP should be discontinued when the prevalence of the mutant Pfdhps K540E exceeded 95% and the prevalence of the mutant Pfdhps A581G exceeded 10%, as SP was likely to be ineffective36. In the current WHO guidelines, the prevalence of mutations associated with SP resistance is no longer a prerequisite for the use of IPTp-SP7. A study of SP resistance across Africa from 1990 to 2020 showed that the mutant Pfdhps A437G was very common across Africa, the mutant Pfdhps K540E was highly prevalent in East and Southeast Africa and relatively low in other regions of Africa, and the mutant Pfdhps A581G was identified across Africa, but its prevalence was relatively low37. Similarly, our study showed the frequency of the mutant Pfdhps A437G, K540E, and A581G alleles at 84.4%, 3.4%, and 9.8%, respectively. The prevalence of K540E was relatively low and was mainly identified in Liberia. The prevalence of A581G was close to 10% and was mainly detected in Nigeria. It was previously reported that mutants Pfdhps A581G and A613S were detected in the absence of K540E in West Africa24, which our study confirmed. Furthermore, K540E was always detected as coexistent with A437G. The mutant Pfdhps I431V was first identified in Nigeria, then its prevalence increased and was subsequently reported in countries of West and Central Africa38,39. Our study found the I431V mutation in samples from six countries, with the highest prevalence in Nigeria. Similarly, mutant I431V was detected in the absence of K540E. There were eight haplotypes harboring the I431V mutation. The most common haplotypes were VAGKGS (7.5%, 35/469) and VAGKAA (2.1%, 10/469), and were mainly observed in Nigeria. Nevertheless, the effect on SP chemoprevention of the I431V mutation and haplotypes containing it remains unknown. The quintuple mutant haplotype I51R59N108 - G437E540 is considered the fully SP-resistant haplotype. This haplotype is reportedly uncommon in West Africa compared with eastern and southern Africa39. Similarly, the frequency of I51R59N108 - G437E540 was just 3.4% in our study and was identified in five countries, occurring most often in Liberian samples. As the mutants Pfdhps A581G and A613S were detected in the absence of K540E in West Africa, the super resistant haplotype was not found in our study. The partially resistant haplotype was most prevalent in West Africa (72.6%), with the predominant haplotypes being I51R59N108 - G437 (39.1%) and I51R59N108 - A436G437 (16.0%). The identified haplotype containing the most mutant codons is the octuple mutant haplotype I51R59N108 - V431A436G437G581S613. It occurred at a frequency of 7.3%, mostly in Nigeria. While the octuple mutant haplotype was limited in the West and Central Africa regions17, it may spread to other regions soon. It is urgent to make a surveillance of the prevalence of the octuple mutant haplotype and its effects on SP. SMC is the intermittent administration of a curative dose of antimalarial medicine during the malaria season, regardless of whether the child is infected with malaria. The objective of SMC is to establish antimalarial drug concentrations in the blood that clear existing infections and prevent new ones during the period of greatest malaria risk. Some prospective trials and ecological studies of SMC with SP + amodiaquine (AQ) in West Africa have reported increased prevalence of the dhfr/dhps quadruple and quintuple mutants, other studies have found no evidence of selection39. No evidence has been reported of SMC being followed by increased prevalence of the higher level resistance mutations that most severely impair curative SP efficacy, nor does SMC appear to select for parasites carrying mutations associated with diminished AQ susceptibility. The ability of SP to clear existing infections and prevent new ones is compromised in areas of high to very high resistance, but the intervention still reduces low birthweight and maternal anaemia. So, SP should continue to be used in areas of high SP resistance until more effective alternatives for malaria chemoprevention are found. This study was limited by some factors. First, the isolates were from Chinese citizens returning from West Africa and not from infants and pregnant women in West Africa. Thus, these samples could be used only to evaluate the molecular epidemiology of SP resistance, not to investigate the efficacy of SP chemoprevention. Furthermore, the samples were not obtained using statistical sampling methods. They were passively collected from returning citizens, and sample sizes were uneven among the countries as well as the years, especially from 2020 to 2022. This might explain why the mutant prevalence in the Pfdhps gene, including I431V, S436A/F, A437G, K540E, A581G, and A613S alleles, all showed a trend toward increasing from 2012 to 2022; however, the changes were not statistically significant. Conclusion Our study observed a high mutant prevalence of the Pfdhfr and Pfdhps genes associated with SP resistance among the P. falciparum isolates imported from West Africa during 2012–2022. The mutant prevalence of single nucleotide polymorphisms in the Pfdhfr gene had sustained a high level for the 10-year period, while mutants in the Pfdhps gene showed an increasing trend. The mutant Pfdhps I431V, A581G, and A613S alleles had the highest frequency in Nigeria compared with other countries, while the mutant Pfdhps K540E was at the highest frequency in Liberia. The partially resistant haplotype was the most common in West Africa. The fully resistant haplotype I51R59N108 - G437E540 was at a low prevalence of 3.4% and mainly occurred in Liberia, and the super resistant haplotype was not found in our study. The mutant Pfdhps I431V and the octuple mutant haplotype I51R59N108 - V431A436G437G581S613 showed an increasing trend, and more research about this octuple mutant and its effects is urged. Although the fully resistant haplotype had low prevalence and the super resistant haplotype was rare, the partially resistant haplotype was common. SP should continue to be used in areas of high SP resistance until more effective alternatives for malaria chemoprevention are found. Meanwhile, it is essential to continuously monitor the status of the Pfdhfr and Pfdhps genes in West Africa with the goal of better implementation of preventive treatment policies for infants and pregnant women. Methods Sample collection Data about the imported P. falciparum cases were collected from the Disease Surveillance Information Report Management system of the China Center for Disease Control and Prevention. Anticoagulated whole blood samples were collected from patients. The patients were diagnosed with malaria initially by blood smear microscopy and/or rapid diagnosis test (RDT) in the local hospital or County Centers for Disease Control and Prevention. The anticoagulated whole blood and blood smear samples of the cases were collected before antimalarial treatment and deposited in the Sample Resource Library in Henan Provincial Reference Laboratory for Malaria Diagnosis. All of the cases were confirmed to be infected with malaria parasite species using nested PCR (in 2011–2017) or qPCR (after 2017) and blood smear microscopy performed at the Henan Provincial Reference Laboratory for Malaria Diagnosis. DNA extraction and amplification The genomic DNA was extracted from the whole-blood samples using QIAamp DNA Blood Mini Kits (Qiagen Inc., Germany) according to the manufacturer’s instructions. The target genes Pfdhfr and Pfdhps were amplified using nested PCR with previously described primers and conditions40,41. The amplified sequence of the Pfdhfr gene contained the codons 16, 51, 59, 108, and 164, and the Pfdhps gene harbored the codons 431, 436, 437, 540, 581, and 613. The secondary PCR products were sequenced bidirectionally by Sangon Biotech Co., Ltd. (Shanghai, China). Data analysis The forward and reverse sequences of the Pfdhfr and Pfdhps genes were assembled through the ChromasPro software version 1.5 (https://technelysium.com.au/wp/chromaspro/). MEGA7 (Molecular Evolutionary Genetics Analysis, https://www.megasoftware.net/show_eua) software was used to identify the mutations by aligning the amplified sequence with the reference genomes. The reference genomes of Pfdhfr and Pfdhps were retrieved from Genbank, and the Genbank IDs of the Pfdhfr and Pfdhps genes were PF3D7_0417200 and PF3D7_1324800, respectively. Chi-square or Fisher’s exact test was used to compare differences in prevalence using SPSS version 21.0 (Statistical Product and Service Solutions), and a two-sided p-value of < 0.05 was considered statistically significant. Acknowledgements We thank all the patients who participated in these surveys and the staff of the hospitals and centers for disease control and prevention in Henan Province. Author contributions R.Z., H.Z., and Y.D. conceived and designed the study. P.J., S.L., S.R. and C.Y. performed the experiments. R.Z. was responsible for the data analysis and drafted the manuscript. D.W. and Y.L. participated in the sample collection. Z.H. and D.Q. contributed to the data collection. H.Z. and Y.D. revised the manuscript. Y.D. and D.L. provided the administrative coordination. All authors contributed to the article and approved the submitted version. We declare no conflicts of interest. Funding This study was sponsored by Henan Province Medical Science and Technology Research Plan Joint Construction Project (LHGJ20220157, LHGJ20210134). Data availability The original data supporting the conclusions of this article will be made available, further inquiries can be directed to the corresponding authors. Declarations Competing interests The authors declare no competing interests. Ethics statement This study was approved by the Ethical Committee of Henan Province Center for Disease Control and Prevention. The patients/participants provided their written informed consent to participate in this study. All the identifiers of patients were removed from the data. All the methods were performed in accordance with the relevant guidelines and regulations of the Henan Province Center for Disease Control and Prevention. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Hongwei Zhang, Email: zhwei69@163.com. Yan Deng, Email: sunnydeng310@163.com. References Associated Data Data Availability Statement The original data supporting the conclusions of this article will be made available, further inquiries can be directed to the corresponding authors.